Cord blood transplantation using tacrolimus and MMF as GVHD prophylaxis

Cord blood transplantation using tacrolimus and MMF as GVHD prophylaxis - FBMTG-CBT2011

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006339

Enrollment

Registered

2011-09-13

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AML, ALL, CML, MDS, ML, ATLL

Interventions

CBT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. available for suitable cord blood stem cells 2. performance status 0-2 3. preserved organ function

Exclusion criteria

Exclusion criteria: 1.not sensitive to chemotherapy 2.complicated infection 3.positive for HBV,HCV,HIV 4.double cancer

Design outcomes

Primary

Measure	Time frame
Adverse effects more than grade3 within 100 days after CBT	—

Countries

Japan

Contacts

Public ContactToshihiro Miyamoto

Kyushu University Hospital Hematology & Oncology

toshmiya@intmed1.med.kyushu-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026